Loading...
XKRX
095700
Market cap141mUSD
Dec 05, Last price  
5,040.00KRW
1D
0.90%
1Q
-7.86%
Jan 2017
-88.32%
IPO
-71.28%
Name

Genexine Inc

Chart & Performance

D1W1MN
XKRX:095700 chart
P/E
—
P/S
71.23
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.27%
Rev. gr., 5y
-23.65%
Revenues
2.93b
-33.75%
6,251,652,91032,519,853,39211,351,915,01428,454,503,37112,881,557,48211,303,045,03018,543,494,61636,828,454,64516,139,032,1664,426,626,9902,932,736,000
Net income
-63.71b
L-4.74%
-2,096,046,609-1,426,677,194-30,932,738,688-19,329,560,416-34,066,759,817-16,509,197,49227,569,725,330-47,726,585,050-56,274,592,376-66,873,517,570-63,705,875,000
CFO
-1.65b
L-95.67%
1,668,236,620-1,642,633,914-14,099,260,886-26,104,449,145-20,054,235,453-41,571,708,994-22,690,958,697-12,745,359,886-39,799,586,489-38,054,511,580-1,648,409,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.
URL
http://genexine.com/
IPO date
Sep 15, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT